Documentos de Académico
Documentos de Profesional
Documentos de Cultura
HTA en DT2
Hipertensión
Hipertrofia VI
Fibrosis Insufic. cardíaca
Remodelación MUERTE
Cardiopatía isquémica
Apoptosis
Receptor-AT1
Tasa filtración glomerular
Proteinuria Falla renal
Esclerosis glomerular
Lancet 2003
IECAs vs ARAs, ensayos clínicos
- Valsartan vs lisinopril e HCTZ
J Clin Pharmacol 1997;37:101–107.
- Eprosartan vs enalapril
Eficacia y seguridad: J Hum Hypertens 1999;13:413–417.
Iguales o muy similares. - Irbesartan vs enalapril
Am J Cardiol 1997;80:1613–1615.
Tolerabilidad: - Candesartan vs enalapril o HCTZ
Am J Hypertens 2000;13:504–511.
ARAs mejor que IECAs.
- Losartan vs captopril
Acta Cardiol 1997;52:495–506.
- Telmisartan vs enalapril
Adv Ther 1998;15:229–240.
Confidentiality Notice
This file is private and may contain confidential and proprietary information. If you have received this file in error, please notify us and remove
it from your system and note that you must not copy, distribute or take any action in reliance on it. Any unauthorized use or disclosure of the contents of this
file is not permitted and may be unlawful. AstraZeneca PLC, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA, UK, T: +44(0)203
Regresión de retinopatía diabética en diabetes tipo 2.
749 5000, www.astrazeneca.com
22
Ogihara T et al. Expert Rev Cardiovasc Ther 2008;6:1195-1201.
Igual tasa de eventos
entre candesartán y
amlodipina
Confidentiality Notice
This file is private and may contain confidential and proprietary information. If you have received this file in error, please notify us and remove
it from your system and note that you must not copy, distribute or take any action in reliance on it. Any unauthorized use or disclosure of the contents of this
file is not permitted and may be unlawful. AstraZeneca PLC, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA, UK, T: +44(0)203
749 5000, www.astrazeneca.com
23
Ogihara T et al. Expert Rev Cardiovasc Ther 2008;6:1195-1201.
E igual mortalidad
Confidentiality Notice
This file is private and may contain confidential and proprietary information. If you have received this file in error, please notify us and remove
it from your system and note that you must not copy, distribute or take any action in reliance on it. Any unauthorized use or disclosure of the contents of this
file is not permitted and may be unlawful. AstraZeneca PLC, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA, UK, T: +44(0)203
749 5000, www.astrazeneca.com
24
Ogihara T et al. Expert Rev Cardiovasc Ther 2008;6:1195-1201.
Significativa reducción de
la hipertrofia del VI,
mayor con candesartán
que con amlodipina
Confidentiality Notice
This file is private and may contain confidential and proprietary information. If you have received this file in error, please notify us and remove
it from your system and note that you must not copy, distribute or take any action in reliance on it. Any unauthorized use or disclosure of the contents of this
file is not permitted and may be unlawful. AstraZeneca PLC, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA, UK, T: +44(0)203
749 5000, www.astrazeneca.com
25
Ogihara T et al. Expert Rev Cardiovasc Ther 2008;6:1195-1201.
Significativa reducción en la
incidencia de nuevos casos
de diabetes con
candesartán, especialmente
en pacientes con sobrepeso
u obesidad
Confidentiality Notice
This file is private and may contain confidential and proprietary information. If you have received this file in error, please notify us and remove
it from your system and note that you must not copy, distribute or take any action in reliance on it. Any unauthorized use or disclosure of the contents of this
file is not permitted and may be unlawful. AstraZeneca PLC, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA, UK, T: +44(0)203
749 5000, www.astrazeneca.com
26
Ogihara T et al. Expert Rev Cardiovasc Ther 2008;6:1195-1201.
Adherencia a 1 año de fármacos antihipertensivos
64%
65
* P<0.007 ARA II vs. IECAs
60 58%
55
50%
(%) 50
43%
45
Los ARA II, por su larga vida media y muy baja tasa de efectos adversos,
38%
40 se asocian a mejor adherencia en pacientes hipertensos.
Esto es altamente desesable en esta población.
35
Diuréticos Beta Bloq Bloq Cálc IECA ARA II
100
▪ Existe una significativa diferencia farmacológica candesartán
entre los diferentes ARA II. 80 telmisartán
olmesartán
Dissociation t1/2
Cellular Endocrinology. 2009; 302:237–243. Material confidencial. Exclusivo para uso interno © AstraZeneca 2019
Candesartán vs losartán - Reducción neta de la PAS
35 Losartán
12
48
13
88
91
90
38
58
69
3
95
92
71
52
38
25
18
67
58
45
39
31
25
20
17
14
11
Can.
29
91
60
91
85
42
42
75
80
02
21
2
78
79
59
43
25
15
73
62
48
40
33
27
22
18
15
13
10
Material confidencial. Exclusivo para uso interno © AstraZeneca 2019
Hipertensión arterial
¿Por qué usar combinaciones de antihipertensivos?
1 2 3 4
No. promedio de medicamentos antihipertensivos
Bakris et al. Am J Med 2004;116(5A):30S–8
Dahlöf et al. Lancet 2005;366:895–906
Fundamento y racional de las combinaciones en hipertensión
Combinación del bloqueador del SRAA con diuréticos o bloqueantes cálcicos
Candesartán: mayor reducción de la TA incluso si el paciente olvida una dosis que losartán
Koenig W et al, on behalf of the Carlos Study Investigators. Clin Drug Invest 2000; 19 (4): 239-246.
Lacourciere Y, Asmar R. A Comparison of the Efficacy and Duration of Action of Candesartan Cilexetil and Losartan as Assessed by Clinic
Candesartán: mayor reducción de la TA incluso si el paciente olvida una dosis que losartán
and Ambulatory Blood Pressure After a Missed Dose, in Truly Hypertensive Patients. Amer Jour of Hyper, 1999;12:1181–1187.
CHARM Trial
Pfeffer MA et al, for the CHARM Investigators and Committees: the CHARM-Overall programme. Lancet 2003 362: 759–66.
Granger CB et al, for the CHARM Investigators and Committees: the CHARM-Alternative trial. Lancet 2003; 362: 772–776.
McMurray JJV et al, for the CHARM Investigators and Committees: the CHARM-Added trial. Lancet 2003; 362: 767–71.
Yusuf S et al, for the CHARM Investigators and Committees: the CHARM Preserved Trial. Lancet 2003; 362: 777–81.
CHARM Trial
7,601 patients with heart failure
3 Individual component randomized trials with the ARB candesartan (4
or 8 mg/day, titrated to target dose of 32 mg) or placebo
Pfeffer MA et al, for the CHARM Investigators and Committees: the CHARM-Overall programme. Lancet 2003 362: 759–66.
Granger CB et al, for the CHARM Investigators and Committees: the CHARM-Alternative trial. Lancet 2003; 362: 772–776.
McMurray JJV et al, for the CHARM Investigators and Committees: the CHARM-Added trial. Lancet 2003; 362: 767–71.
Yusuf S et al, for the CHARM Investigators and Committees: the CHARM Preserved Trial. Lancet 2003; 362: 777–81.
CHARM Overall Program
Mensajes para llevar a casa